Intravenous (IV) and oral omadacycline or approved in October

recently, Paratek Pharmaceuticals announced that the U.SFDA(antimicrobialdrug(Consultation(the Committee voted in favor of approving intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSI) (17 to 1 votes), and community-acquired bacterial pneumonia (CABP) (14 to 4 votes)The FDA is expected to make a decision in early Octoberabout OmadacyclineOmadacycline is a new antibiotic under development with a daily IV and oral two formulations that can be used to treat CABP, ABSSSI and urinary tract infections (UTI)as a modern tetracycline, omadacycline can overcome the resistance of tetracycline and exhibit activity in broad-spectrum bacteria, including gram-positive bacteria, gram-negative bacteria, anaerobic bacteria, atypical bacteria and other drug-resistant strains, Omadacycline has been awarded the FDA-awardedof Qualified Infectious DiseasesProducts (Qualified Infectious Disease Syd) and Fast Track, and itsnew drug(applications for CABP and ABSSSI) have also been qualified for priority reviewthe advisory committee's approval of Omadacycline was based on a review of data on its global research and development projectsthe project included three completed phase 3 studies assessing the safety and efficacy of daily IV and oral omadacycline treatments for ABSSSI and CABP in all three studies, omadacycline met all major and minor end points of efficacy specified by the FDA and was safe and tolerable As part of the clinical trial , nearly 2,000 adult patients received daily madacycline treatment in addition to seeking approval in the U.S., Paratek plans to seek a listing license in the European Union In addition, the company (and signed a cooperation agreement with the Pharmaceutical ("The project is to develop and promote omadacycline in Greater China)